Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. The company was founded in 2006 and is based in Cambridge, Massachusetts.
The FDA has granted rare pediatric disease designation to Dicerna Pharmaceuticals' (DRNA) nedosiran, an investigational RNAi therapy being developed as a once-monthly treatment for primary hyperoxaluria, a family of ultra-rare, life-threatening genetic disorders that cause complications in the kidneys.Rare Pediatric Disease Designation provides for the issuance of a rare pediatric disease...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
On June 10, Chair of the Federal Reserve Jerome Powell cautioned that an economic recovery won't be quick or painless. Considering Wall Street had already priced in a relatively optimistic recovery scenario, it's not too surprising Powell's comments popped the stock market's rally. It doesn't help that a handful of states are reporting case and hospitalization figures that suggest a second wave of coronavirus infections -- and subsequently, more restrictions on movement -- could be on the horizon.